NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA. Halle (Saale) / Munich, Germany, March […]
HALLE (SAALE) / MUNICH, GERMANY, March 7, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Halle (Saale) / Munich, Germany and Nanjing, China, February 28, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and […]
HALLE (SAALE) / MUNICH, GERMANY, January 4, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Halle (Saale) / Munich, Germany December 22, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]
HALLE (SAALE) / MUNICH, GERMANY, November 4, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]
Halle (Saale) / Munich, Germany, November 1, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]
This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014 Halle (Saale) / Munich, Germany October 18, 2021 – Vivoryon Therapeutics N.V. […]
Strategic regional licensing partnership with Simcere Pharmaceutical Group to treat AD in Greater China US Phase 2 VIVA-MIND study for varoglutamstat in AD initiated as planned […]